Lesaffre Probiotic Wins Irritable Bowel Syndrome Health Claim in Canada
Lesaffre has licensed ibSium exclusively in Canada to a company called Medical Futures Inc., which plans to launch an IBS product in the near future.
Photo © iStockphoto.com/Artem_Furman
French probiotic supplier Lesaffre Human Care has secured a Health Canada claim linking its ibSium-brand Saccharomyces cerevisiae strain with benefits for irritable bowel syndrome.
Products in Canada can now claim that ibSium “helps to reduce abdominal pain and discomfort associated with irritable bowel syndrome.” The company’s scientific substantiation includes a clinical trial1 published in the journal Digestive and Liver Disease in 2015 that found Saccharomyces cerevisiae to be well tolerated and to “reduce abdominal pain and discomfort scores without stool modification.” The study was conducted in 179 adults with irritable bowel syndrome who received 500-mg once daily of ibSium Saccharomyces cerevisiae.
For now, Lesaffre has licensed ibSium exclusively in Canada to a company called Medical Futures Inc., a wholly owned subsidiary of Tribute Pharmaceuticals Canada Inc. Lesaffre reports that Medical Futures plans to launch a finished product called ibSium in Canada.
“Obtaining this new health claim is a big win for Lesaffre Human Care,” said the company via press release. “It is a recognition of the company’s long-term investment in providing strong scientific and clinical data to substantiate the benefits of its patented strain of Saccharomyces cerevisiae in individuals with irritable bowel syndrome.”
Irritable bowel syndrome sufferers are many, and many are looking for support, said Lesaffre’s global marketing manager, Sandrine Cuisenier, in the press release. “With millions of people worldwide affected by IBS, many of them unsatisfied with their current treatment, this claim approval will definitely have a positive impact on sales.”
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
References:
1. Pineton de Chambrun G et al., “A randomized clinical trial of Saccharomyces cerevisiae vs. placebo in the irritable bowel syndrome,” Digestive and Liver Disease, vol. 47, no. 2 (February 2015): 119-124
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
U.S. Hemp Authority announces Adult Use Hemp Product Certification Program
April 15th 2024The U.S. Hemp Authority (USHA) has announced the launch of its Adult Use Hemp Product Certification Program in an effort to “reshape public policy around hemp, and to build confidence among retailers and consumers alike.”
